HOME >> MEDICINE >> NEWS
OSA 'Frontiers in Optics' annual meeting celebrates 90th anniversary of innovation in optics

The Optical Society of America's (OSA) Annual Meeting, Frontiers in Optics 2006, will cover the breadth of optical science and engineering. This meeting, co-located with Laser Science XXII, the annual meeting of the American Physical Society (APS) Division of Laser Science, unites these communities for five days of cutting-edge content, powerful networking and opportunities for scientific exchange. Exhibits featuring 80+ leading optics companies will complement the in-depth educational programming and offer attendees a glimpse of the latest optical technologies and products.

WHAT: The Optical Society of America's Annual Meeting Frontiers in Optics 2006

WHERE: Rochester Convention Center, Rochester, New York, USA

WHEN: Sunday, October 8 Thursday, October 12

WHY COME PROGRAM HIGHLIGHTS: Frontiers in Optics 2006 marks 90 years of optics innovation as the 90th Annual Meeting of the Optical Society of America. Highlights include:

  • Frontiers in Optics plenary session will focus on timely global issues, highlighting solutions in optics.

Featured sessions are:

  • The Energy Problem and What We Can Do About It, Steven Chu, Nobel Laureate, 1997 Nobel Prize in Physics, Lawrence Berkeley Natl. Lab, USA
  • Optics Meets Alzheimer's Disease: Seeing the Way to a Cure, Lee Goldstein, Harvard Medical School, USA

Technical topic highlights include:

  • The use of photon imaging to monitor blood flow in mice after stroke
  • Advances in imaging the eye in optical exams and studies of the eye; improved retinal imaging and eye examinations for people with diabetic retinopathy, an eye disorder that strike 40-45 percent of those diagnosed with diabetes
  • New methods of producing 3-D images in displays without the need for special glasses
  • Prototype system that produces color images in an endoscope, used in examinations of the esophagus and
    '"/>


Contact: Keira Shein
keira@wilkinsonshein.com
410-363-9494
Optical Society of America
11-Sep-2006


Page: 1 2

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. UGA study finds that violence costs nation $70 billion annually
3. Consumer-driven health plans slow to catch on, 2nd annual survey finds
4. Education and the gerontological imagination: GSAs annual meeting to present new research on aging
5. ASTRO annual meeting again named a fastest growing tradeshow
6. Study shows lawn mowers injure thousands of US children annually
7. UK aging expert signs on as keynote speaker for GSAs annual meeting
8. Half a million lives lost annually in Europe to preventable injuries
9. Penn Scientist receives first annual prize for scientific contributions to womens health
10. Strategy to redesign primary care medicine presented at annual internal medicine conference
11. ACP releases annual report on The State of the Nations Health Care

Post Your Comments:
(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: